
    
      This is an open-label, single dose study in 6 healthy male subjects aged 18 to 55 years. Each
      subject will be admitted to the clinical pharmacology unit on the day prior to dosing Check
      in (Day -1) and will remain in the clinical pharmacology unit until up to at least target Day
      8 (168 hours post-dose).

      All subjects will receive 3000 mg AZD0914 incorporating 18.5 MBq (500 Ci) of [14C]
      administered as a single oral dose following at least an 8 hour fast from food. Subjects can
      have water. For specific food and water restrictions.

      This study will investigate the metabolic fate and routes of excretion of AZD0914.
    
  